Cabernet Pharmaceuticals

Cabernet Pharmaceuticals is a biotechnology company specializing in the discovery of small molecule therapeutics through the application of advanced computational informatics and structural biology. The company primarily focuses on modulating the Sigma-1 and Sigma-2 receptors, which are implicated in a variety of pathological conditions including neurodegeneration, chronic pain, and oncology. Cabernet utilizes its proprietary technology to identify and optimize novel ligands that can cross the blood-brain barrier and exhibit high selectivity. Their research has been supported by numerous federal grants, particularly from the National Institutes of Health (NIH), to advance candidates for neuropathic pain and Alzheimer's disease. By integrating high-throughput screening data with molecular modeling, the company aims to streamline the drug development process for complex CNS disorders.